Steve Schonfeld’s Perspective Therapeutics CATX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$79K Buy
+28,746
New +$87.2K ﹤0.01% 2516
2026
Q1
– Sell
-62,370
Closed -$172K – 2267
2025
Q4
$172K Buy
+62,370
New +$178K ﹤0.01% 1744
2025
Q3
– Sell
-143,332
Closed -$493K – 2233
2025
Q2
$493K Buy
+143,332
New +$378K ﹤0.01% 1546
2025
Q1
– Sell
-168,500
Closed -$538K – 2223
2024
Q4
$538K Sell
168,500
-423,123
-72% -$3.45M ﹤0.01% 1357
2024
Q3
$7.9M Buy
591,623
+65,823
+13% +$875K 0.05% 370
2024
Q2
$5.24M Buy
525,800
+242,760
+86% +$3.51M 0.03% 534
2024
Q1
$3.37M Buy
+283,040
New +$2.41M 0.02% 790

Other funds holding CATX

Steve Schonfeld's CATX Position: Q3 2026 in Review

Steve Schonfeld opened a new position in Perspective Therapeutics (CATX) in Q3 2026: 28,746 shares worth $79K. The stake represents ﹤0.01% of the portfolio and ranks #2516 among its holdings. This is a return to the name: Steve Schonfeld previously reported a position in CATX as recently as Q4 2025.

Steve Schonfeld first reported a position in CATX in Q1 2024 and has held it in 7 quarters since. The position peaked at $7.9M in Q3 2024. 118 funds tracked by Wall St. Rank hold CATX as of Q3 2026.

  • Steve Schonfeld held 28,746 shares of Perspective Therapeutics worth $79K as of Q3 2026.
  • Perspective Therapeutics was a new Steve Schonfeld position in Q3 2026.
  • Perspective Therapeutics made up ﹤0.01% of Steve Schonfeld's portfolio in Q3 2026, its #2516 holding.
  • Steve Schonfeld first reported a position in Perspective Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • Steve Schonfeld's Perspective Therapeutics position peaked at $7.9M in Q3 2024.
  • 118 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q3 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.